Literature DB >> 26055425

The 3q29 deletion confers >40-fold increase in risk for schizophrenia.

J G Mulle1,2.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26055425      PMCID: PMC4546529          DOI: 10.1038/mp.2015.76

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


× No keyword cloud information.
The 1.4-Mb deletion on chromosome 3q29 was first described in 2005 and is associated with a range of neurodevelopmental phenotypes, including developmental delay, intellectual disability (ID) and autism.[1] Prior data has implicated the same deletion as a suggestive or significant risk factor for schizophrenia (SZ),[2, 3, 4] but the low frequency of the deletion has rendered individual samples underpowered to confirm this association, and prohibited an accurate estimate of risk. However, since the initial reports many more SZ samples with copy-number variation (CNV) data have been published, and in aggregate is possible to arrive at a more accurate estimate of SZ risk for this genetic lesion. Toward this goal, a meta-analysis was conducted according to Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines:[5] a search of PubMed on 19 November 2014 for the keywords ‘schizophrenia CNV' resulted in 195 studies. A second search for ‘rare chromosomal schizophrenia' revealed 154 studies largely but not completely overlapping the initial set. Only case–control studies were considered. Criteria for inclusion into this meta-analysis included: sampling of cases and controls in the primary study (case-only studies and case reports were excluded); interrogation of the 3q29 genomic interval in cases and controls (by genome-wide methods, region-specific probes or other assays directly targeting the region); and reporting of all rare CNV found in both cases and controls (in the primary paper or a supplement). Reasons for excluding the studies were: the study was a case report; the study was about a psychiatric disorder other than SZ; or the paper was a review and did not contain primary data. Frequently, multiple papers were published on a progressively larger sample, where data from earlier papers are contained in later papers with additional study subjects included (for example, Rees et al.[6, 7]; Szatkiewicz et al.[4, 8]; Mulle et al.[2, 9]) In these instances, to avoid ‘double-counting' of the data and inflating the risk estimate, we included for analysis purposes the paper with the largest and most complete data collection (in these three cases, the most recent paper). Sixteen studies, contributing 17 distinct samples, fit all inclusion criteria.[3, 4, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21] From the final list of these qualifying papers, data for the 3q29 region were extracted (Table 1), representing 25 314 SZ cases and 62 432 controls. Overlapping data were identified in one instance: 590 cases (including one deletion carrier) and 439 controls were reported in Szatkiewicz et al.[4] and International Schizophrenia Consortium[20]; data were subtracted from the total reported in the more recent publication. In most papers, controls were ethnically matched to cases (Table 1, ‘ethnically matched'). Three papers used population-based, unscreened controls;[14, 15, 17] another used publicly available data as a comparison sample;[6] and the remainder used controls that were screened in some way for psychiatric illness. Determination of cases status was highly heterogeneous among studies; most studies used one or more standardized instruments along with case notes, medical records, history of hospitalizations and/or informant interviews to arrive at a diagnosis. A single study used childhood-onset cases[13] (‘childhood-onset schizophrenia' in Table 1) and a second study used SZ cases with ID.[11] For two studies, clinical trial participants were included.[6, 10] The size of the reported variant was consistent among studies, with most reports indicating a 1.3–1.6 Mb deletion, which removes all 22 protein-coding genes in the interval. One report indicated a slightly smaller 837 kb deletion (although all but two genes in the typical deletion interval were removed)[9] and two reports could not resolve the size because individual probes[15] or limited markers[17] were used for detection. For this meta-analysis, an overall (raw) odds ratio and a Cochran–Mantel–Haenszel (CMH)-adjusted odds ratio were calculated. The results of this analysis indicate that the 3q29 deletion confers a 41.1-fold increased risk for SZ (P-value 5.8 × 10−8, 95% confidence interval 5.6–1953.6). To assess whether any one sample was exerting undue influence on the risk estimate, each sample was removed and the CMH-adjusted odds ratio was recalculated. The range of OR estimates (33.3–41.1) suggests that larger samples may be exerting upward influence on the estimate of risk, but no one sample is driving the observed effect size. Typical estimates for effect sizes of other SZ-associated CNV ranged from 5 to 30[22]; thus, the 3q29 deletion may be the single-largest risk factor for SZ, surpassing even the 22q11.2 deletion. The 22 protein-coding genes in the 3q29 deletion interval deserve scrutiny as molecular targets that, when haploinsufficient, may underlie at least one form of SZ. Several candidate genes have been implicated in the region, including DLG1, PAK2 and FBXO45. This meta-analysis highlights the utility of large samples to identify rare genetic variants with high risk for severe psychiatric disease.
Table 1

Meta-analysis of 3q29 deletion and schizophrenia

Ref.EthnicitySelection of controlsSZ casesCase 3q29 delControlsControl 3q29 delCMH OR (95% CI, P-value) with this sample removed
Levinson et al.[3]European AmericanEM266742648036.4 (4.7 –1799.3, 8.4e−07)
Levinson et al.[3]African AmericanEM12731963040.2 (5.4–1924.3, 1.0e−07)
Szatkiewicz et al.[4]SwedishEM412955478033.4 (4.2–1695.3, 3.4e−06)
Rees et al.[6]Mixed (95% European ancestry)EM6882411 255033.3 (4.2–1691.5, 2.6e−06)
Mulle et al.[9]Ashkenazi JewishEM55411014039.0 (5.2–1882.6, 1.6e−07)
Walsh et al.[10]Mixed (78% Caucasian)EM1501256039.1 (5.3–1887.4, 1.5e−07)
Rudd et al.[11]No information (recruited from Iowa)No information (recruited from Iowa)166052041.1 (5.6–1953.6, 5.8e−08)
Derks et al.[12]Scottish (ID with SZ)Scottish (ID w/o SZ)64066041.1 (5.6–1953.6, 5.8e−08)
Ahn et al.[13]COS: ‘highly heterogeneous'Unaffected sibs of cases126069041.1 (5.6–1953.6, 5.8e−08)
Priebe et al.[14]GermanEM163701627041.1 (5.6–1953.6, 5.8e−08)
Van Den Bossche et al.[15]Belgian, Swedish, ScottishEM125921173038.9 (5.2–1881.2, 2.1e−07)
Buizer-Voskamp et al.[16]DutchEM8341672040.1 (5.4–1922.3, 1.0e−07)
Stefansson et al.[17]Northern European/EuropeanEM1438033,2461∞ (6.7–∞, 2.7e−08)
Magri et al.[18]ItalianEM1721160040.0 (5.4–1917.5, 1.1e−07)
Xu et al.[19]Afrikaner SZ trios (de novo CNV)Afrikaner control trios (de novo CNV)1520156041.1 (5.6–1953.6, 5.8e−08)
International Schizophrenia Consortium[20]Mixed EuropeanEM339123181038.9 (5.2–1880.7, 2.1e−07)
Costain et al.[21]European ancestryEM4200416041.1 (5.6–1953.6, 5.8e−08)
Total25 3142262 4321 
Raw OR54.3 (95% CI: 8.8–2215.7, P-value 2.2e−11)
CMH OR41.1 (95% CI: 5.6–1953.6, P-value 5.8e−08)

Abbreviations: CI, confidence interval; CNV, copy number variation; CMH, Cochran–Mantel–Haenszel; COS, childhood-onset schizophrenia; EM, ethnically matched; ID, intellectual disability; OR, odds ratio; SZ, schizophrenia.

  21 in total

1.  Pathogenic rare copy number variants in community-based schizophrenia suggest a potential role for clinical microarrays.

Authors:  Gregory Costain; Anath C Lionel; Daniele Merico; Pamela Forsythe; Kathryn Russell; Chelsea Lowther; Tracy Yuen; Janice Husted; Dimitri J Stavropoulos; Marsha Speevak; Eva W C Chow; Christian R Marshall; Stephen W Scherer; Anne S Bassett
Journal:  Hum Mol Genet       Date:  2013-06-27       Impact factor: 6.150

2.  Genome-wide analysis shows increased frequency of copy number variation deletions in Dutch schizophrenia patients.

Authors:  Jacobine E Buizer-Voskamp; Jan-Willem Muntjewerff; Eric Strengman; Chiara Sabatti; Hreinn Stefansson; Jacob A S Vorstman; Roel A Ophoff
Journal:  Biol Psychiatry       Date:  2011-04-13       Impact factor: 13.382

3.  Microdeletions of 3q29 confer high risk for schizophrenia.

Authors:  Jennifer Gladys Mulle; Anne F Dodd; John A McGrath; Paula S Wolyniec; Adele A Mitchell; Amol C Shetty; Nara L Sobreira; David Valle; M Katharine Rudd; Glen Satten; David J Cutler; Ann E Pulver; Stephen T Warren
Journal:  Am J Hum Genet       Date:  2010-08-13       Impact factor: 11.025

4.  Rare chromosomal deletions and duplications increase risk of schizophrenia.

Authors: 
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

5.  Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia.

Authors:  Tom Walsh; Jon M McClellan; Shane E McCarthy; Anjené M Addington; Sarah B Pierce; Greg M Cooper; Alex S Nord; Mary Kusenda; Dheeraj Malhotra; Abhishek Bhandari; Sunday M Stray; Caitlin F Rippey; Patricia Roccanova; Vlad Makarov; B Lakshmi; Robert L Findling; Linmarie Sikich; Thomas Stromberg; Barry Merriman; Nitin Gogtay; Philip Butler; Kristen Eckstrand; Laila Noory; Peter Gochman; Robert Long; Zugen Chen; Sean Davis; Carl Baker; Evan E Eichler; Paul S Meltzer; Stanley F Nelson; Andrew B Singleton; Ming K Lee; Judith L Rapoport; Mary-Claire King; Jonathan Sebat
Journal:  Science       Date:  2008-03-27       Impact factor: 47.728

6.  Strong association of de novo copy number mutations with sporadic schizophrenia.

Authors:  Bin Xu; J Louw Roos; Shawn Levy; E J van Rensburg; Joseph A Gogos; Maria Karayiorgou
Journal:  Nat Genet       Date:  2008-05-30       Impact factor: 38.330

7.  Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications.

Authors:  Douglas F Levinson; Jubao Duan; Sang Oh; Kai Wang; Alan R Sanders; Jianxin Shi; Nancy Zhang; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Kenneth S Kendler; Robert Freedman; Frank Dudbridge; Itsik Pe'er; Hakon Hakonarson; Sarah E Bergen; Ayman H Fanous; Peter A Holmans; Pablo V Gejman
Journal:  Am J Psychiatry       Date:  2011-02-01       Impact factor: 18.112

8.  New copy number variations in schizophrenia.

Authors:  Chiara Magri; Emilio Sacchetti; Michele Traversa; Paolo Valsecchi; Rita Gardella; Cristian Bonvicini; Alessandra Minelli; Massimo Gennarelli; Sergio Barlati
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

9.  Analysis of copy number variations at 15 schizophrenia-associated loci.

Authors:  Elliott Rees; James T R Walters; Lyudmila Georgieva; Anthony R Isles; Kimberly D Chambert; Alexander L Richards; Gerwyn Mahoney-Davies; Sophie E Legge; Jennifer L Moran; Steven A McCarroll; Michael C O'Donovan; Michael J Owen; George Kirov
Journal:  Br J Psychiatry       Date:  2013-12-05       Impact factor: 9.319

10.  Large recurrent microdeletions associated with schizophrenia.

Authors:  Hreinn Stefansson; Dan Rujescu; Sven Cichon; Olli P H Pietiläinen; Andres Ingason; Stacy Steinberg; Ragnheidur Fossdal; Engilbert Sigurdsson; Thordur Sigmundsson; Jacobine E Buizer-Voskamp; Thomas Hansen; Klaus D Jakobsen; Pierandrea Muglia; Clyde Francks; Paul M Matthews; Arnaldur Gylfason; Bjarni V Halldorsson; Daniel Gudbjartsson; Thorgeir E Thorgeirsson; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Aslaug Jonasdottir; Asgeir Bjornsson; Sigurborg Mattiasdottir; Thorarinn Blondal; Magnus Haraldsson; Brynja B Magnusdottir; Ina Giegling; Hans-Jürgen Möller; Annette Hartmann; Kevin V Shianna; Dongliang Ge; Anna C Need; Caroline Crombie; Gillian Fraser; Nicholas Walker; Jouko Lonnqvist; Jaana Suvisaari; Annamarie Tuulio-Henriksson; Tiina Paunio; Timi Toulopoulou; Elvira Bramon; Marta Di Forti; Robin Murray; Mirella Ruggeri; Evangelos Vassos; Sarah Tosato; Muriel Walshe; Tao Li; Catalina Vasilescu; Thomas W Mühleisen; August G Wang; Henrik Ullum; Srdjan Djurovic; Ingrid Melle; Jes Olesen; Lambertus A Kiemeney; Barbara Franke; Chiara Sabatti; Nelson B Freimer; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Ole A Andreassen; Roel A Ophoff; Alexander Georgi; Marcella Rietschel; Thomas Werge; Hannes Petursson; David B Goldstein; Markus M Nöthen; Leena Peltonen; David A Collier; David St Clair; Kari Stefansson
Journal:  Nature       Date:  2008-09-11       Impact factor: 49.962

View more
  21 in total

Review 1.  Unraveling the genetic architecture of copy number variants associated with schizophrenia and other neuropsychiatric disorders.

Authors:  Timothy P Rutkowski; Jason P Schroeder; Georgette M Gafford; Stephen T Warren; David Weinshenker; Tamara Caspary; Jennifer G Mulle
Journal:  J Neurosci Res       Date:  2016-11-08       Impact factor: 4.164

2.  NCBP2 modulates neurodevelopmental defects of the 3q29 deletion in Drosophila and Xenopus laevis models.

Authors:  Mayanglambam Dhruba Singh; Matthew Jensen; Micaela Lasser; Emily Huber; Tanzeen Yusuff; Lucilla Pizzo; Brian Lifschutz; Inshya Desai; Alexis Kubina; Sneha Yennawar; Sydney Kim; Janani Iyer; Diego E Rincon-Limas; Laura Anne Lowery; Santhosh Girirajan
Journal:  PLoS Genet       Date:  2020-02-13       Impact factor: 5.917

Review 3.  Autism spectrum disorder and schizophrenia: An updated conceptual review.

Authors:  Amandeep Jutla; Jennifer Foss-Feig; Jeremy Veenstra-VanderWeele
Journal:  Autism Res       Date:  2021-12-29       Impact factor: 5.216

Review 4.  New discoveries in schizophrenia genetics reveal neurobiological pathways: A review of recent findings.

Authors:  Alex V Kotlar; Kristina B Mercer; Michael E Zwick; Jennifer G Mulle
Journal:  Eur J Med Genet       Date:  2015-10-19       Impact factor: 2.708

Review 5.  Diagnostic and therapeutic potential of microRNAs in neuropsychiatric disorders: Past, present, and future.

Authors:  Begum Alural; Sermin Genc; Stephen J Haggarty
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-04-09       Impact factor: 5.067

6.  Convergent and distributed effects of the 3q29 deletion on the human neural transcriptome.

Authors:  Esra Sefik; Ryan H Purcell; Elaine F Walker; Gary J Bassell; Jennifer G Mulle
Journal:  Transl Psychiatry       Date:  2021-06-15       Impact factor: 6.222

7.  Functional assessment of the "two-hit" model for neurodevelopmental defects in Drosophila and X. laevis.

Authors:  Lucilla Pizzo; Micaela Lasser; Tanzeen Yusuff; Matthew Jensen; Phoebe Ingraham; Emily Huber; Mayanglambam Dhruba Singh; Connor Monahan; Janani Iyer; Inshya Desai; Siddharth Karthikeyan; Dagny J Gould; Sneha Yennawar; Alexis T Weiner; Vijay Kumar Pounraja; Arjun Krishnan; Melissa M Rolls; Laura Anne Lowery; Santhosh Girirajan
Journal:  PLoS Genet       Date:  2021-04-05       Impact factor: 6.020

8.  Caregiver Perspectives on a Child's Diagnosis of 3q29 Deletion: "We Can't Just Wish This Thing Away".

Authors:  Megan R Glassford; Ryan H Purcell; Sarah Pass; Melissa M Murphy; Gary J Bassell; Jennifer G Mulle
Journal:  J Dev Behav Pediatr       Date:  2022 Feb-Mar 01       Impact factor: 2.225

9.  Craniofacial features of 3q29 deletion syndrome: Application of next-generation phenotyping technology.

Authors:  Bryan C Mak; Rossana Sanchez Russo; Michael J Gambello; Nicole Fleischer; Emily D Black; Elizabeth Leslie; Melissa M Murphy; Jennifer Gladys Mulle
Journal:  Am J Med Genet A       Date:  2021-05-03       Impact factor: 2.802

10.  Novel features of 3q29 deletion syndrome: Results from the 3q29 registry.

Authors:  Megan R Glassford; Jill A Rosenfeld; Alexa A Freedman; Michael E Zwick; Jennifer G Mulle
Journal:  Am J Med Genet A       Date:  2016-01-06       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.